Ironwood Pharmaceuticals Q2 2021 Earnings Report
Key Takeaways
Ironwood Pharmaceuticals reported a strong second quarter in 2021, with U.S. LINZESS net sales increasing by 18% year-over-year to $259 million and total revenue increasing by 16% year-over-year to $104 million. The company's GAAP net income was $391 million, which included a $338 million non-recurring income tax benefit. Ironwood ended the quarter with $493 million in cash and cash equivalents and raised its full-year 2021 financial guidance.
U.S. LINZESS net sales of $259 million, an increase of 18% year-over-year
Total revenue of $104 million, an increase of 16% year-over-year, driven primarily by U.S. LINZESS collaboration revenue of $100 million
GAAP net income of $391 million, includes a $338 million non-recurring income tax benefit related to the release of the valuation allowance against the majority of the company’s deferred tax assets
Adjusted EBITDA of $65 million; ended Q2 2021 with $493 million in cash and cash equivalents
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals
Forward Guidance
Ironwood is raising its 2021 financial guidance due to the growth in U.S. LINZESS prescription demand.